 To expand its footprint in eye care, AbbVie Inc. ABBV , Financial has struck a billion-dollar deal to gain access to a gene therapy used to treat several common kinds of eye disease. The Chicago-area pharma giant announced Monday that it will be collaborating with Regenxbio Inc. RGNX , Financial on the Maryland-based drugmakers treatment called RGX-314. 